Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

NASDAQ Listing: 5.75 Million Shares: 12 M+ In Cash+ Major Partners

|Includes: AVXL, Celgene Corporation (CELG), GILD, GIMU, IPIX

Global Immune (NASDAQ: GBIC) appears as a very attractive situation for hedge funds, merger and acquisition investors. Celgene (NASDAQ:CELG)recently exercised it 's option to continue the development license with GI 6207, which will add 1.9 million to GI's already adequate 12+ million cash position. The Celgene license could pay Global Immune approx. 120 million dollars if clinical success continues. What a tremendous non dilutive pipe potential. Yes, the company has had its troubles, and now desires to be bought out, or sell, or merge with new management.http://www.denverpost.com/business/ci_28640807/half-dozen-employees-globeimmune-weighs-sale see Gilead (NASDAQ:GILD).

If Global Immune, is sold to a major or taken private, this will be a great waste of a well structured stock company with a NASDAQ symbol, with an enviable stock structure. The right non NASDAQ pharmaceutical with a lot of potential blockbuster product and scientific success could make a tremendous merger candidate and no doubt retain and add to the current institutional interest and loyalty that Global Immune has. It could become an secondary way of restructuring the share structure of a merging company.

I realize that some things as great as they may seem are just are not meant to come together. However, I own shares of several bulletin board pharmaceuticals including AVXL, that I think could swing a deal with Cantor Fitzgerald, that would reward existing Global Immune shareholders handsomely. The instutional money watching AVXL might come pouring in. What do you think?

I wonder how Global Immune, would look with CTIX's mouth watering, PolyMedix Assets acquire for a miniscule 4+ million dollars. I would imagine that its less than 20 million capitalization as listed by Google Finance, would rocket to not less than 1 billion dollars, with the potential of a lion share of the financing of Brilacidin FDA stage 3 generated internally. The same corporate genius that acquired PMX assets is yet managing them.

Being on the pink sheets or for that matter the OTCBB, can be like owning a Beverly Hills Manse ground bound in the ghetto. Even, if its worth a million, your only going to get $100,000 for it. That's an effective short attack in and of itself.

I think much better minds than mine, are at work at Cantor Fitzgerald. They will help find a tremendous acquisition or merger candidate. The recent market turbulence actually makes public funding more skittish and difficult. Having sizable cash and pending development milestone payments, Global Immune looks like a bear market paradise.

I do have hedge fund managers, members of the financial press and others that view my blogs and respond. Your quick comments will echo loud.

Some Genius Might Be Listening

Ella Ruth

Disclosure: I am/we are long OVER 10,000 SHARES IN 3 STOCKS MENTIONED.

Additional disclosure: I may buy more Global Immune, AVXL and CTIX anytime.